(3.234.143.26)
Users online: 2689    [ij] [ij] [ij] 
Email id
 

Research Journal of Pharmaceutical Dosage Forms and Technology
Year : 2015, Volume : 7, Issue : 2
First page : ( 111) Last page : ( 117)
Print ISSN : 0975-234X. Online ISSN : 0975-4377.
Article DOI : 10.5958/0975-4377.2015.00016.6

Design, Development and Evaluation of Solifenacin Succinate Tablets

Sudha R. K.V. Naga1,*,*****, Kishore V. Sai1,**, Babu CH. Venu1,***, Jitendranath E.2,****

1Bapatla College of Pharmacy, Bapatla -522101, Guntur (District), Andhra Pradesh (state), India

2AKRG College of Pharmacy, Vijayawada, A.P.

*Corresponding Author E-mail: nagasudharkv@gmail.com

**voiceofsaikishore@yahoo.com

***pharmacistvenu@gmail.com

****ejitendranath@gmail.com

***Address for correspondence: R. K.V. Naga Sudha, Bapatla College of Pharmacy, Bapatla -522101, Guntur (District), Andhra Pradesh (state), India.

Online published on 25 June, 2015.

Abstract

Solifenacin Succinate is used in the treatment of over active bladder with symptoms of urge urinary incontinence, urgency, and increased urinary frequency, and anti spasmodic. Solifenacin Succinate was launched in 2005 and has been shown in both short and long term clinical trials to fulfill these requirements. Solifenacin is a competitive M3 receptor antagonist with a long half-life (45–68 hours). It is available in two dosage strengths namely a 5 or 10 mg once-daily tablet. Ten different trial batches were carried out using different concentrations of excipients like binder (Methocel E5 premium LV), super disintegrant (sodium starch glycolate, cross carmellose sodium, cross povidone), lubricant (Magnesium stearate), glidant (Aerosil) by direct compression technique. The pre-compression parameters and post compression parameters of Solifenacin Succinate tablets were evaluated. The tablets were evaluated for in-vitro drug release studies. Based on similarity factor f2 cross povidone (1.17%), Methocel E5 premium LV (3%), Magnesium starate (1.47%), Aerosil (0.529%) was selected.

Top

Keywords

Solifenacin Succinate, Urinary incontinence, Overactive bladder, Muscarinic receptor antagonist, Direct compression.

Top

  
║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
446,236,953 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.